BioCatalystWatch
IVAWorkspace / IVA / OverviewCompany library
Price
Market cap
Next catalyst4Q 2026lanifibranor — NATiV3 · Phase 3 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

lanifibranor

PPARα × PPARδ × PPARγ

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

lanifibranor

PPARα × PPARδ × PPARγ

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Shares outstanding

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

IVA SEC archive